Baiyunshan Pharmaceutical's Unit Amends Production License

MT Newswires Live

04/10

Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.

The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.

The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2526553552"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2526553552\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2526553552?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-10 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526553552","market":"hk","top_or_hot":-1,"title":"Baiyunshan Pharmaceutical's Unit Amends Production License","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.</p><p>The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.</p><p>The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharmaceutical's Unit Amends Production License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharmaceutical's Unit Amends Production License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-10 18:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.</p><p>The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.</p><p>The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526553552","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526553552","pubTimestamp":1744279688,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical's  unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","BK1606":"中医药概念","BK0097":"医药电商","BK0028":"国家队","BK0239":"医药制造","BK1197":"保健护理产品经销商","00874":"白云山","BK1521":"挪威政府全球养老基金持仓","BK0070":"员工持股","BK1515":"抗疫概念","BK0096":"民营医院","BK0183":"MSCI概念","BK1191":"制药","BK0188":"融资融券"},"translate_title":"白云山药业单位修改生产许可证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"00874":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}